1h Free Analyst Time
The gastrointestinal diseases therapeutics market is forecasted to grow by USD 18.52 billion during 2023-2028, accelerating at a CAGR of 6.81% during the forecast period. The report on the gastrointestinal diseases therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing incidence of gastrointestinal diseases, new gastrointestinal therapeutics product launches, and increasing demand for biologics and targeted therapies.
The gastrointestinal diseases therapeutics market is segmented as below:
By Drug Class
- Anti-inflammatory and immunosuppressors
- Acid neutralizers
- Others
By Type
- Branded
- Generics
By Geographical Landscape
- North America
- Asia
- Europe
- Rest of World (ROW)
The report on the gastrointestinal diseases therapeutics market covers the following areas:
- Gastrointestinal diseases therapeutics market sizing
- Gastrointestinal diseases therapeutics market forecast
- Gastrointestinal diseases therapeutics market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Opportunity/Restraints
11 Competitive Landscape
12 Competitive Analysis
13 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global gastrointestinal diseases therapeutics market: Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corp., Eisai Co. Ltd., Eli Lilly and Co., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck and Co. Inc., Novartis AG, Olympus Corp., Ovesco Endoscopy AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., and UCB SA.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is availability of nutritional therapies."
According to the report, one of the major drivers for this market is the increasing incidence of gastrointestinal diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Bayer AG
- Biogen Inc.
- Boehringer Ingelheim International GmbH
- Boston Scientific Corp.
- Eisai Co. Ltd.
- Eli Lilly and Co.
- GlaxoSmithKline Plc
- Johnson and Johnson Services Inc.
- Merck and Co. Inc.
- Novartis AG
- Olympus Corp.
- Ovesco Endoscopy AG
- Pfizer Inc.
- Sanofi SA
- Takeda Pharmaceutical Co. Ltd.
- UCB SA
